|1.||Dartois, Nathalie: 14 articles (04/2014 - 01/2005)|
|2.||Nicolau, David P: 14 articles (01/2014 - 01/2005)|
|3.||Dowzicky, Michael J: 14 articles (01/2013 - 07/2005)|
|4.||Jones, Ronald N: 13 articles (06/2013 - 07/2004)|
|5.||Curcio, Daniel: 12 articles (06/2011 - 09/2005)|
|6.||Hsueh, Po-Ren: 10 articles (06/2015 - 01/2005)|
|7.||Falagas, Matthew E: 10 articles (01/2015 - 07/2008)|
|8.||Dukart, Gary: 10 articles (07/2014 - 07/2008)|
|9.||Eckmann, Christian: 9 articles (10/2015 - 11/2010)|
|10.||Bassetti, Matteo: 8 articles (10/2015 - 01/2010)|
03/01/2009 - "Despite the proven efficacy of tigecycline in the treatment of infections caused by these pathogens, questions remain as to the exposure-response relationship best associated with its efficacy. "
07/01/2005 - "A preliminary pharmacokinetic (PK)/pharmacodynamic analysis in experimental animal models of infection indicates that the efficacy of tigecycline is probably best predicted by the ratio of the area under the concentration-time curve to the minimum inhibitory concentration. "
07/01/2010 - "Recent data suggest that tigecycline, a novel antibiotic with broad-spectrum antibacterial activity, can be used successfully to treat patients with severe Clostridium difficile infection. "
03/01/2010 - "Tigecycline appears to be effective for the successful treatment of PDR infections"
07/01/2009 - "The outbreak of infections treated with tigecycline was successfully eliminated in conjunction with an aggressive infection control strategy."
10/01/2005 - "Global clinical trials are underway to further assess the efficacy of tigecycline for community- and hospital- acquired pneumonia. "
11/01/2011 - "The clinical resolution rate from such pneumonia might reflect the ultimate efficacy of tigecycline in treating MDRAB pneumonia and the overall efficacy might be overestimated."
01/01/2013 - "The objective of this study is to review the literature about the efficacy of tigecycline in community-acquired pneumonia. "
12/01/2011 - "The aim of this study was to evaluate the efficacy of tigecycline in multidrug-resistant (MDR) Acinetobacter baumannii pneumonia. "
05/01/2014 - "The goal of our research was to assess the clinical efficacy of tigecycline at different doses by using a pharmacokinetic/pharmacodynamic (PK/PD) model which can incorporate pharmacokinetic data of tigecycline from patients with pneumonia and MICs of MDR-Ab from a tertiary hospital. "
06/01/2009 - "Tigecycline is the first member of the closely related glycylglycines and, due to its broad antimicrobial spectrum, it is considered useful in the treatment of sepsis. "
01/01/2015 - "pneumoniae isolates in neonatal septicemia, to check antimicrobial susceptibility to various drugs including tigecycline; and to assess burden of multiple drug resistance (MDR). "
11/01/2013 - "Under tigecycline treatment, the patient developed a sepsis caused by a carbapenem-susceptible ST258 K. "
02/01/2009 - "By contrast, tigecycline seems not appropriate for treatment sepsis and similar acute life-threatening bacterial diseases."
04/27/2012 - "We report a case of safe and effective use of tigecycline in the treatment of Leuconostoc catheter-related line sepsis in a neutropenic patient. "
|4.||Soft Tissue Infections
07/01/2013 - "Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies."
10/01/2015 - "Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria."
07/01/2013 - "Tigecycline is an approved treatment for complicated skin and soft-tissue infections (cSSTIs). "
05/01/2012 - "Tigecycline was given for soft-tissue infection in both cases. "
08/01/2011 - "To gain additional data concerning the anti-anaerobic activity of tigecycline in serum, we analyzed blood samples from six patients with a complicated skin/soft tissue infection who were receiving IV tigecycline 50 mg every 12 h. "
|5.||Critical Illness (Critically Ill)
10/01/2015 - "Tigecycline alone or in combination therapy was an effective and safe antibiotic treatment in critically ill and antimicrobially pre-treated patients with NSTI frequently caused by resistant pathogens."
01/01/2011 - "Only few data are available on the efficacy of tigecycline in critically ill patients. "
03/01/2015 - "Our results contribute to the need for new studies to determine the safety of tigecycline use, especially for the treatment of critically ill patients. "
11/01/2013 - "Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline."
07/01/2013 - "The safety and tolerability of tigecycline, alone and in combination, are consistent with the level of critical illness among patients in these real-life studies."
|6.||CL 331002 (glycylcycline)
|10.||imipenem drug combination cilastatin (Primaxin)